{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Chang EL"],"funding":["Project Data Sphere"],"pagination":["e011049"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC11979595"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["13(4)"],"pubmed_abstract":["Ophthalmic immune-related adverse events (Eye-irAEs) from immune checkpoint inhibitors can cause visual morbidity. The absence of standardized definitions for Eye-irAEs not only impedes the development of evidence-based treatments but also progress in translational research. The objective of this study was to develop consensus guidance for an approach to Eye-irAEs.Four ophthalmic physicians (uveitis specialists and neuro-ophthalmologists) drafted Eye-irAE consensus guidance and definitions, which were reviewed by the multidisciplinary Eye-irAE definition panel. The panel was divided into Group A (Neuro-ophthalmology/Orbital Disease) and Group B (Uveitis/Ocular Surface Disease). A modified Delphi consensus process was used, with two rounds of anonymous ratings by panelists and two meetings "],"journal":["Journal for immunotherapy of cancer"],"pubmed_title":["Consensus disease definitions for ophthalmic immune-related adverse events of immune checkpoint inhibitors."],"pmcid":["PMC11979595"],"funding_grant_id":["N/A"],"pubmed_authors":["Shariff A","Reynolds KL","Mantopoulos D","Chang EL","Chen JJ","Liu R","Yoon MK","Berkenstock M","DeLott LB","Sen HN","Rine J","Huynh K","Pless M","Bhatti MT","Egan RA","Sobrin L","McDunn J","Costello F","Papaliodis G","Freitag SK","Fraser CL","Subramanian PS","Gangaputra S","Johnson DB","Kombo N","Gordon LK","Rubin KM","Lee AG","Keyhanian K","Chodosh J","Kramer M","Pimkina J","Lobo-Chan AM","Tsui E","Chwalisz BK","Dinkin M","Levy M","Dalvin LA","Guidon AC"],"additional_accession":[]},"is_claimable":false,"name":"Consensus disease definitions for ophthalmic immune-related adverse events of immune checkpoint inhibitors.","description":"Ophthalmic immune-related adverse events (Eye-irAEs) from immune checkpoint inhibitors can cause visual morbidity. The absence of standardized definitions for Eye-irAEs not only impedes the development of evidence-based treatments but also progress in translational research. The objective of this study was to develop consensus guidance for an approach to Eye-irAEs.Four ophthalmic physicians (uveitis specialists and neuro-ophthalmologists) drafted Eye-irAE consensus guidance and definitions, which were reviewed by the multidisciplinary Eye-irAE definition panel. The panel was divided into Group A (Neuro-ophthalmology/Orbital Disease) and Group B (Uveitis/Ocular Surface Disease). A modified Delphi consensus process was used, with two rounds of anonymous ratings by panelists and two meetings ","dates":{"release":"2025-01-01T00:00:00Z","publication":"2025 Apr","modification":"2025-07-07T03:10:06.964Z","creation":"2025-07-07T03:10:06.964Z"},"accession":"S-EPMC11979595","cross_references":{"pubmed":["40199607"],"doi":["10.1136/jitc-2024-011049"]}}